rabbit anti-drd2  (Merck & Co)

Journal: Nature Communications

Article Title: Non-canonical interplay between glutamatergic NMDA and dopamine receptors shapes synaptogenesis

doi: 10.1038/s41467-023-44301-z

Figure Lengend Snippet:

Article Snippet: rabbit anti-D2R , 55084-1-AP , Proteintech , 2 μg.

Techniques:

Journal: Cancer genetics

Article Title: Hypomethylation of DRD2 promotes breast cancer through the FLNA-ERK pathway.

doi: 10.1016/j.cancergen.2023.09.001

Figure Lengend Snippet: Fig. 1. DMCs identified in the DRD2 promoter region of breast cancer tissues (C1-C7) to the paired adjacent tissues (N1-N7). (A) A heatmap of the 8 DMCs in the breast cancer tissues. (B) The mean methylation level, differences, and significance level of these DMCs. (C) The methylation level of these DMCs in cancer tissues and their paired adjacent tissues (negative control).

Article Snippet: Antibodies against DRD2 (SC-5303, Santa, USA), ERK (4695S, CST, USA), p-ERK (4370S, CST, USA), and α-tublin (66,031–1-ig, proteintech, USA) were used for Western blot analysis.

Techniques: Methylation, Negative Control

Journal: Cancer genetics

Article Title: Hypomethylation of DRD2 promotes breast cancer through the FLNA-ERK pathway.

doi: 10.1016/j.cancergen.2023.09.001

Figure Lengend Snippet: Fig. 3. Construction of DRD2 overexpression and downregulation models. (A) Representative immunoblot of DRD2 expression of the original MCF-7 cells (Con), MCF-7 with blank vector (NC), and MCF-7 with DRD2 overexpression (OE). (B) The quantification of DRD2 in MCF-7 cells by western blot. (C) Representative immunoblot of DRD2 expression of the original MB231 cells (Con), MB231 with non-target siRNA (shNC), and MB231 with three different shRNAs (shRNA1, shRNA2, shRNA3). (D) The quantification of DRD2 in MB231 cells by western blot. * vs Hs 578Bst/con, P<0.05; # vs NC/shNC, P < 0.05.

Article Snippet: Antibodies against DRD2 (SC-5303, Santa, USA), ERK (4695S, CST, USA), p-ERK (4370S, CST, USA), and α-tublin (66,031–1-ig, proteintech, USA) were used for Western blot analysis.

Techniques: Over Expression, Western Blot, Expressing, Plasmid Preparation

Journal: Cancer genetics

Article Title: Hypomethylation of DRD2 promotes breast cancer through the FLNA-ERK pathway.

doi: 10.1016/j.cancergen.2023.09.001

Figure Lengend Snippet: Fig. 2. The expression levels of DRD2 in breast cancer cells. (A) Representative immunoblot of DRD2 expression of the breast cancer cells (MCF-7, SK-BR3, and MB231) and normal breast cells (Hs 578Bst). (B-C) The relationship between DRD2 and β-actin was detected by PCR, and the relationship between DRD2 and α-tublin was detected by western blot. * vs Hs 578Bst, P<0.05.

Article Snippet: Antibodies against DRD2 (SC-5303, Santa, USA), ERK (4695S, CST, USA), p-ERK (4370S, CST, USA), and α-tublin (66,031–1-ig, proteintech, USA) were used for Western blot analysis.

Techniques: Expressing, Western Blot

Journal: Cancer genetics

Article Title: Hypomethylation of DRD2 promotes breast cancer through the FLNA-ERK pathway.

doi: 10.1016/j.cancergen.2023.09.001

Figure Lengend Snippet: Fig. 4. DRD2 promotes the proliferation and migration of breast cancer cells. (A) Proliferation of MB231 treated with different concentrations of 5-AzadC. (B) Proliferation of original MCF-7 cells (Con), MCF-7 with blank vector (NC), and MCF-7 with DRD2 overexpression (OE). (C) Proliferation of original MB231 cells (Con), MB231 with non-target siRNA (shNC), MB231 with DRD2 shRNA (shRNA), and MB231 with DRD2 shRNA plus 5-AzadC (shRNA + 5-AzadC). (D) Statistics for migration of Con, NC, and OE cells. (E) Representative cell images for the migration ability of Con, NC, and OE cells. (F) Statistics for migration of Con, shNC, shRNA, and shRNA + 5-AzadC cells. (G) Representative cell images for the migration ability of Con, shNC, shRNA, and shRNA + 5-AzadC cells. * vs con, P < 0.05; # vs NC/ shNC, P < 0.05; $ vs shRNA, P < 0.05.

Article Snippet: Antibodies against DRD2 (SC-5303, Santa, USA), ERK (4695S, CST, USA), p-ERK (4370S, CST, USA), and α-tublin (66,031–1-ig, proteintech, USA) were used for Western blot analysis.

Techniques: Migration, Plasmid Preparation, Over Expression, shRNA

Journal: Cancer genetics

Article Title: Hypomethylation of DRD2 promotes breast cancer through the FLNA-ERK pathway.

doi: 10.1016/j.cancergen.2023.09.001

Figure Lengend Snippet: Fig. 5. DRD2 promotes cancer through ERK signaling pathway. (A) Western blot for DRD2, ERK and p-ERK expression in primary MCF-7 cells (Con), blank vector (NC) and DRD2 overexpressing (OE). (B-E) Quantitative analysis of FLNA, ERK, p-ERK and DRD2 expression in different MCF-7 cells. (F) Western blot of DRD2 expression in primary MB231 cells (Con), MB231 and non-target siRNA (shNC), MB231 and DRD2 shRNA (shRNA), MB231 and DRD2 shRNA + 5-AzadC (shRNA + 5- AzadC) . (G-J) Quantitative analysis of FLNA, ERK, p-ERK and DRD2 expression in different MB231 cells.

Article Snippet: Antibodies against DRD2 (SC-5303, Santa, USA), ERK (4695S, CST, USA), p-ERK (4370S, CST, USA), and α-tublin (66,031–1-ig, proteintech, USA) were used for Western blot analysis.

Techniques: Western Blot, Expressing, Plasmid Preparation, shRNA

Journal: Cancer genetics

Article Title: Hypomethylation of DRD2 promotes breast cancer through the FLNA-ERK pathway.

doi: 10.1016/j.cancergen.2023.09.001

Figure Lengend Snippet: Fig. 6. The expression of DRD2 regulated tumor growth in vivo. (A, D) Subcutaneous xenograft model images of blank vector (NC) and DRD2-overexpressing MCF-7 cells (OE) in nude mice and their tumors. (B) Tumor growth curves of NC group and OE group. (C) Tumor weights in NC group and OE group. (E) Expression of Ki67 and CD31 in NC and OE tissues.

Article Snippet: Antibodies against DRD2 (SC-5303, Santa, USA), ERK (4695S, CST, USA), p-ERK (4370S, CST, USA), and α-tublin (66,031–1-ig, proteintech, USA) were used for Western blot analysis.

Techniques: Expressing, In Vivo, Plasmid Preparation

Journal: Cancer genetics

Article Title: Hypomethylation of DRD2 promotes breast cancer through the FLNA-ERK pathway.

doi: 10.1016/j.cancergen.2023.09.001

Figure Lengend Snippet: Fig. 7. Detection of protein levels in subcutaneous tumor tissue. (A) Western blot analysis of FLNA, DRD2, ERK and p-ERK expression in MCF-7-NC and MCF-7-OE tissues. (B) Quantitative analysis of FLNA, ERK, p-ERK and DRD2 expression in MCF-7-NC and MCF-7-OE tissues. (C) Representative immunoblots of FLNA, DRD2, ERK and p-ERK expression in MB231-shNC, MB231-shRNA and MB231-shRNA+5-AzadC tissues. (D) Quantitative analysis of FLNA, ERK, p-ERK, DRD2 expression in MB231-shNC, MB231-shRNA, MB231-shRNA+5-AzadC tissues.

Article Snippet: Antibodies against DRD2 (SC-5303, Santa, USA), ERK (4695S, CST, USA), p-ERK (4370S, CST, USA), and α-tublin (66,031–1-ig, proteintech, USA) were used for Western blot analysis.

Techniques: Western Blot, Expressing, shRNA